“Mesothelioma Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Mesothelioma Market.

The Mesothelioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Mesothelioma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Mesothelioma treatment therapies with a considerable amount of success over the years. 

• Mesothelioma companies working in the treatment market are The Netherlands Cancer Institute, Bristol-Myers Squibb, PrECOG, LLC., Memorial Sloan Kettering Cancer Center, ETOP IBCSG Partners Foundation, MedImmune LLC, Åslaug Helland, AstraZeneca, Oncotelic Inc., Hyogo Medical University, Trizell Ltd, RS Oncology LLC, Vivace Therapeutics, Inc, TCR2 Therapeutics, Sanofi, ImmVira Pharma Co. Ltd, TCR2 Therapeutics, CRISPR Therapeutics, Biotheus Inc., and others, are developing therapies for the Mesothelioma treatment 

• Emerging Mesothelioma therapies in the different phases of clinical trials are- Pembrolizumab, Nivolumab, Durvalumab, Sacituzumab govitecan-hziy, Carboplatin, Tremelimumab, ipilimumab, Volrustomig, OT-101, Lenvatinib, rAd-IFN, RSO-021, VT3989, gavo-cel, THOR-707, T3011, TC-510, CTX131, PM8002, and others are expected to have a significant impact on the Mesothelioma market in the coming years.   

• In March 2024, Ultimovacs, a clinical-stage biotechnology company, has released data from the Phase II NIPU trial of its UV1 cancer vaccine. This investigator-initiated, open-label, multi-center Phase II trial evaluated the impact of incorporating the UV1 cancer vaccine into second-line treatment with ipilimumab and nivolumab for patients with pleural mesothelioma.

• In December 2023, Sellas Life Sciences, a US-based late-stage clinical biopharmaceutical company, announced that its Phase I study (NCT02737787) of galinpepimut-S combined with Opdivo (nivolumab) has successfully met its primary endpoint, showing improved overall survival in mesothelioma patients.

Mesothelioma Overview

Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (mesothelium). The most common form is pleural mesothelioma, which affects the lining of the lungs and is often associated with exposure to asbestos fibers. Other less common forms include peritoneal mesothelioma (affecting the lining of the abdomen), pericardial mesothelioma (affecting the lining around the heart), and mesothelioma of the tunica vaginalis (affecting the lining of the testes).

Get a Free Sample PDF Report to know more about Mesothelioma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/mesothelioma-pipeline-insight

Emerging Mesothelioma Drugs Under Different Phases of Clinical Development Include:

• Pembrolizumab: The Netherlands Cancer Institute

• Nivolumab: Bristol-Myers Squibb

• Durvalumab: PrECOG, LLC.

• Sacituzumab govitecan-hziy: Memorial Sloan Kettering Cancer Center

• Carboplatin: ETOP IBCSG Partners Foundation

• Tremelimumab: MedImmune LLC

• ipilimumab: Åslaug Helland

• Volrustomig: AstraZeneca

• OT-101: Oncotelic Inc.

• Lenvatinib: Hyogo Medical University

• rAd-IFN: Trizell Ltd

• RSO-021: RS Oncology LLC

• VT3989: Vivace Therapeutics, Inc

• gavo-cel: TCR2 Therapeutics

• THOR-707: Sanofi

• T3011: ImmVira Pharma Co. Ltd

• TC-510: TCR2 Therapeutics

• CTX131: CRISPR Therapeutics

• PM8002: Biotheus Inc.

Mesothelioma Route of Administration

Mesothelioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Mesothelioma Molecule Type

Mesothelioma Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Mesothelioma Pipeline Therapeutics Assessment

• Mesothelioma Assessment by Product Type

• Mesothelioma By Stage and Product Type

• Mesothelioma Assessment by Route of Administration

• Mesothelioma By Stage and Route of Administration

• Mesothelioma Assessment by Molecule Type

• Mesothelioma by Stage and Molecule Type

DelveInsight’s Mesothelioma Report covers around 50+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Mesothelioma product details are provided in the report. Download the Mesothelioma pipeline report to learn more about the emerging Mesothelioma therapies

Some of the key companies in the Mesothelioma Therapeutics Market include:

Key companies developing therapies for Mesothelioma are – Merck & Co., Inc., Bristol-Myers Squibb, AstraZeneca, Roche, Novartis, Pfizer Inc., Eli Lilly and Company, Johnson & Johnson, GlaxoSmithKline plc (GSK), AbbVie Inc., Sanofi, and others.

Mesothelioma Pipeline Analysis:

• The Mesothelioma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Mesothelioma with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mesothelioma Treatment.

• Mesothelioma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Mesothelioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mesothelioma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Mesothelioma drugs and therapies

Mesothelioma Pipeline Market Drivers

• Advancements in Treatment, Targeted Therapies, Immunotherapy Innovations, Early Diagnosis Initiatives, Increased Awareness, are some of the important factors that are fueling the Mesothelioma Market.

Mesothelioma Pipeline Market Barriers

• However, Limited Treatment Option, Diagnostic Challenges, High Development Costs, Patient Heterogeneity, Lack of Funding, and other factors are creating obstacles in the Mesothelioma Market growth.

Scope of Mesothelioma Pipeline Drug Insight    

• Coverage: Global

• Key Mesothelioma Companies: The Netherlands Cancer Institute, Bristol-Myers Squibb, PrECOG, LLC., Memorial Sloan Kettering Cancer Center, ETOP IBCSG Partners Foundation, MedImmune LLC, Åslaug Helland, AstraZeneca, Oncotelic Inc., Hyogo Medical University, Trizell Ltd, RS Oncology LLC, Vivace Therapeutics, Inc, TCR2 Therapeutics, Sanofi, ImmVira Pharma Co. Ltd, TCR2 Therapeutics, CRISPR Therapeutics, Biotheus Inc., and others

• Key Mesothelioma Therapies: Pembrolizumab, Nivolumab, Durvalumab, Sacituzumab govitecan-hziy, Carboplatin, Tremelimumab, ipilimumab, Volrustomig, OT-101, Lenvatinib, rAd-IFN, RSO-021, VT3989, gavo-cel, THOR-707, T3011, TC-510, CTX131, PM8002, and others

• Mesothelioma Therapeutic Assessment: Mesothelioma current marketed and Mesothelioma emerging therapies

• Mesothelioma Market Dynamics: Mesothelioma market drivers and Mesothelioma market barriers 

Request for Sample PDF Report for Mesothelioma Pipeline Assessment and clinical trials

Table of Contents

1. Mesothelioma Report Introduction

2. Mesothelioma Executive Summary

3. Mesothelioma Overview

4. Mesothelioma- Analytical Perspective In-depth Commercial Assessment

5. Mesothelioma Pipeline Therapeutics

6. Mesothelioma Late Stage Products (Phase II/III)

7. Mesothelioma Mid Stage Products (Phase II)

8. Mesothelioma Early Stage Products (Phase I)

9. Mesothelioma Preclinical Stage Products

10. Mesothelioma Therapeutics Assessment

11. Mesothelioma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Mesothelioma Key Companies

14. Mesothelioma Key Products

15. Mesothelioma Unmet Needs

16 . Mesothelioma Market Drivers and Barriers

17. Mesothelioma Future Perspectives and Conclusion

18. Mesothelioma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/